What is 5-Amino-1MQ?
Compound Spotlight
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme increasingly studied for its role in regulating cellular energy metabolism. Unlike most compounds in this catalog, it is not a peptide chain but a small molecule, and this article breaks down what it is, how it is studied, and what the research says so far.
Quick summary
- 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide.
- NNMT consumes SAM (the cell’s universal methyl donor) and diverts nicotinamide away from NAD+ salvage.
- Inhibiting it raises intracellular NAD+ and SAM and suppresses fat-cell lipogenesis — in mice.
- Key result: reduced fat mass in diet-induced obese mice without reducing food intake, which rules out covert appetite suppression.
- Evidence limit worth being blunt about: there are no human trials. Zero human safety or efficacy data.
- The strongest in vivo study ran 11 days with roughly 9 animals per group.
What NNMT actually does
Nicotinamide N-methyltransferase (NNMT) catalyzes a single, simple reaction: it takes a methyl group from S-adenosylmethionine (SAM) and attaches it to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine.
That reaction is cheap to describe and expensive to run. It burns SAM, which is the methyl donor for essentially every methylation reaction in the cell — DNA methylation, histone methylation, polyamine synthesis. And it consumes nicotinamide, which is the primary salvage-pathway precursor for regenerating NAD+. Once nicotinamide has been methylated into 1-MNA, it cannot re-enter the NAD+ salvage pathway. NNMT therefore sits at the junction of two separate metabolic economies and taxes both of them at once.
The reason this became interesting is that NNMT is markedly upregulated in white adipose tissue in obesity and insulin resistance, in both mice and humans. That raised an obvious question: is elevated NNMT a consequence of the metabolic state, or a contributor to it?
The target-validation work
Kraus and colleagues addressed that question in Nature in 2014 using antisense oligonucleotide knockdown of NNMT in white adipose tissue and liver. Mice with NNMT knocked down were protected against diet-induced obesity and showed improved insulin sensitivity. The authors proposed that NNMT influences the adipocyte’s fat-storage program through effects on histone methylation and polyamine flux — in other words, that the methyl-donor drain has downstream consequences for which genes the fat cell expresses.
That study did not involve 5-Amino-1MQ. Its importance is that it established NNMT as functionally involved in obesity rather than merely correlated with it, which is what justified developing pharmacological inhibitors in the first place.
Where 5-Amino-1MQ comes in
Neelakantan, Watowich, and colleagues at the University of Texas ran a structure-activity relationship campaign across quinolinium analogs, published in the Journal of Medicinal Chemistry in 2017. 5-Amino-1MQ emerged as the lead compound, with an IC50 in the low micromolar range and — critically — membrane permeability, which many earlier NNMT inhibitors lacked. An inhibitor that cannot cross the cell membrane cannot reach a cytoplasmic enzyme.
The follow-up in Biochemical Pharmacology in 2018 tested it in diet-induced obese mice. The reported results: reduced body weight, reduced white adipose mass, smaller adipocytes, lower plasma total cholesterol, reduced intracellular 1-MNA (confirming target engagement), and increased intracellular NAD+ and SAM.
The single most important detail in that paper is what did not change: food intake. A great many compounds that appear to reduce fat mass turn out to be working through appetite suppression. Demonstrating fat-mass reduction with food intake held constant is what makes this a mechanistically distinct result rather than another anorectic in disguise.
The evidence ceiling
Here is where the article has to be straightforward with you. There are no human clinical trials of 5-Amino-1MQ. Not zero positive trials — zero trials. No published human pharmacokinetics, no human safety dataset, no human efficacy outcome of any kind.
The in vivo evidence that does exist is also small. The pivotal mouse study ran approximately 11 days with roughly nine animals per group. That is entirely normal and appropriate for an early pharmacology paper — it is proof of concept, and it succeeded at being proof of concept. It is not a basis for inferring effect sizes, durability, or safety in a different species over longer periods.
There is separate human data, but it is worth understanding exactly what it is and is not. Genetic-association work (Bañales-Luna et al., Scientific Reports, 2020) has linked variants near NNMT-related loci to BMI and resting energy expenditure in human cohorts, and epigenetic work (Crujeiras et al., 2018) has identified NNMT-linked signatures in human adipose tissue. These establish that the NNMT axis is metabolically live in humans, not a rodent-only artifact. They say nothing about what happens when you pharmacologically inhibit the enzyme in a person.
Why NAD+ precursors are often discussed alongside it
The pairing logic is straightforward once the pathway is clear: NAD+ precursors add substrate to the salvage pathway, while NNMT inhibition reduces drainage from it. Whether the two are actually additive in practice has not been established in controlled research, and the rationale should be read as a mechanistic hypothesis rather than a demonstrated result.
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule methylquinolinium compound. It is grouped with research peptides commercially, not chemically. This also means peptide-specific handling logic — hydrolysis of peptide bonds, denaturation — does not apply to it in the same way.
Why does “no change in food intake” matter so much?
Because it distinguishes a genuine metabolic mechanism from appetite suppression. If fat mass falls only because the animal ate less, the compound has not demonstrated the mechanism it claims. Holding intake constant is what makes the NNMT result interesting.
How does NNMT inhibition differ from taking NAD+ directly?
They act on opposite sides of the same ledger. NAD+ precursors supply the pathway; NNMT inhibition reduces the loss of nicotinamide out of it. They are complementary in principle, though this has not been tested rigorously in combination.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.
References
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141–152.
- Neelakantan H, et al. Structure-activity relationship of quinolinium NNMT inhibitors. J Med Chem. 2017.
- Kannt A, et al. A small molecule inhibitor of nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018;8(1):3660.
- Bañales-Luna M, et al. Scientific Reports. 2020.
View the 5-Amino-1MQ product listing →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. 5-Amino-1MQ has no human clinical trial data and is not approved by any regulatory authority. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
